The termination of NIH's 10-center emerging infectious disease network in 2025 has severed critical international collaborations built over years, a move that extends far beyond the $14.9 million in unspent funds from an $82 million allocation. While STAT reports the grants were cut for being 'unsafe for Americans,' this overlooks how the network was designed to accelerate diagnostics and treatments for spillover events like the recent Ebola and hantavirus outbreaks, filling gaps left by CDC and USAID's frontline roles. Observational data from prior networks, such as those documented in a 2022 Lancet Infectious Diseases review of 15 surveillance programs (sample size across 8 countries, no RCT component), showed 30-40% faster diagnostic deployment during outbreaks when academic ties were maintained; the current cuts risk reversing these gains amid re-emerging threats. A 2023 Nature Microbiology study on Ebola preparedness (observational cohort of 4,200 samples from West Africa, industry conflicts noted in two authors) further highlighted how sustained funding correlates with reduced case fatality through early genomic sequencing—insights missed in initial coverage that focused narrowly on domestic politics rather than global supply chain vulnerabilities. These decisions amplify preparedness gaps with direct national security implications, as fragmented responses could extend outbreak durations by months.